| Gastrointestinal Stromal Tumors
Ayvakit vs Stivarga
Side-by-side clinical, coverage, and cost comparison for gastrointestinal stromal tumors.Deep comparison between: Ayvakit vs Stivarga with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsStivarga has a higher rate of injection site reactions vs Ayvakit based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Stivarga but not Ayvakit, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Ayvakit
Stivarga
At A Glance
Oral
Daily
KIT/PDGFRA kinase inhibitor
Oral
Once daily (21 of 28 days)
Multikinase inhibitor
Indications
- Gastrointestinal Stromal Tumors
- Aggressive Systemic Mastocytosis
- Indolent Systemic Mastocytosis
- Metastasis from malignant neoplasm of colon and/or rectum
- Gastrointestinal Stromal Tumors
- Liver carcinoma
Dosing
Gastrointestinal Stromal Tumors 300 mg orally once daily in patients with PDGFRA exon 18 mutation-positive unresectable or metastatic GIST; continue until disease progression or unacceptable toxicity.
Aggressive Systemic Mastocytosis 200 mg orally once daily; continue until disease progression or unacceptable toxicity.
Indolent Systemic Mastocytosis 25 mg orally once daily.
Metastasis from malignant neoplasm of colon and/or rectum, Gastrointestinal Stromal Tumors, Liver carcinoma 160 mg orally once daily for the first 21 days of each 28-day cycle, taken after a low-fat meal; continue until disease progression or unacceptable toxicity.
Contraindications
—
—
Adverse Reactions
Most common (>=20%) in GIST edema, nausea, fatigue/asthenia, cognitive impairment, vomiting, decreased appetite, diarrhea, increased lacrimation, abdominal pain, constipation, rash, dizziness, hair color changes
Most common (>=20%) in AdvSM edema, diarrhea, nausea, fatigue/asthenia
Most common (>=10%) in ISM eye edema, dizziness, peripheral edema, flushing
Serious intracranial hemorrhage, anemia, pleural effusion, sepsis, gastrointestinal hemorrhage, subdural hematoma, ascites, pneumonia, acute kidney injury, encephalopathy
Most common (>=20%) pain, HFSR/PPES, asthenia/fatigue, diarrhea, decreased appetite/food intake, hypertension, infection, dysphonia, hyperbilirubinemia, fever, mucositis, weight loss, rash, nausea
Serious hepatotoxicity, infections, hemorrhage, gastrointestinal perforation or fistula, dermatological toxicity, hypertension, cardiac ischemia and infarction, reversible posterior leukoencephalopathy syndrome
Postmarketing hypersensitivity reaction, nephrotic syndrome, cardiac failure, arterial aneurysms/dissections/rupture
Pharmacology
Avapritinib is a tyrosine kinase inhibitor that targets KIT D816V, PDGFRA, and PDGFRA D842 mutants (IC50s <25 nM), inhibiting autophosphorylation and constitutive activation of these receptors to suppress tumor and mast cell proliferation; other potential targets include wild-type KIT, PDGFRB, and CSFR1.
Regorafenib is a small molecule inhibitor of multiple membrane-bound and intracellular kinases involved in oncogenesis, tumor angiogenesis, metastasis, and tumor immunity, including VEGFR1-3, KIT, PDGFR-alpha/beta, FGFR1/2, RAF-1, BRAF, and CSF1R.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Ayvakit
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (0/12) · Qty limit (11/12)
Stivarga
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (0/12) · Qty limit (11/12)
UnitedHealthcare
Ayvakit
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (0/8) · Qty limit (2/8)
Stivarga
- Covered on 4 commercial plans
- PA (8/8) · Step Therapy (0/8) · Qty limit (7/8)
Humana
Ayvakit
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Stivarga
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAccessia Health: Gastrointestinal Stromal Tumors (GIST) - Public Insurance: Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
No savings programs available for Stivarga.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
AyvakitView full Ayvakit profile
StivargaView full Stivarga profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.